HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

HLN

Haleon plc

Healthcare — Drug Manufacturers - Specialty & Generic

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Buy 2.2 / 5 5 analysts
$8.73
$-0.27 (-3.06%)
Target: $11.69 (34.0%)

Price History

52-Week Range
Sign in to add HLN to a watchlist or set price alerts.

Fundamentals

Market Cap$41.40B
P/E Ratio (TTM)19.18
Forward P/E15.55
EPS (TTM)$0.49
Dividend Yield2.05%
Profit Margin15.11%
Revenue Growth0.60%
ROE10.27%
Debt/Equity52.37
Recommendation Buy 2.2
Analyst Target$11.69
Analysts5
Next Earnings Jul 30, 2026 BMO
Indexes -

Technical Indicators

RSI (14)61.3
Beta0.25
SMA 20-
SMA 40-
52-Week High$11.28
52-Week Low$8.65
50-Day Avg$9.16
200-Day Avg$9.69
Avg Volume$8.98M
Volume$8.34M

Performance Analysis

BULLISH

HLN shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($8.65), which could present a value opportunity.
+ RSI at 61.3 shows positive momentum.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 0.6% year-over-year.
+ Wall Street consensus is "Buy" from 5 analysts.
+ Average analyst target of $11.69 implies 34.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:13 UTC

Back to Screener Export Report